• Users Online: 76
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2018  |  Volume : 2  |  Issue : 1  |  Page : 6-11

Analysis of molecular markers in glioblastoma and correlation with survival pattern


1 Department of Pathology, Institute of Human Behaviour and Allied Sciences, New Delhi, India
2 Department of Pathology, All India Institute of Medical Sciences, New Delhi, India
3 Department of Social and Preventive Medicine, University College of Medical Sciences, New Delhi, India
4 Department of Neurosurgery, Institute of Human Behaviour and Allied Sciences, New Delhi, India

Correspondence Address:
Ishita Pant
Department of Pathology, Institute of Human Behaviour and Allied Sciences, Dilshad Garden, New Delhi - 110 095
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijcpc.ijcpc_11_18

Rights and Permissions

Objective: The objective of this study was to apply the newly recommended mandatory immunohistochemical (IHC) markers, isocitrate dehydrogenase (IDH) and ATRX, in addition to our previously applied panel of p53, epidermal growth factor receptor [EGFR], vascular endothelial growth factor [VEGF], MDM2, and Ki67 on histopathologically diagnosed thirty cases of glioblastoma. Their interrelationship and correlation with survival pattern were analyzed. Materials and Methods: A retrospective analysis of the histopathology records and clinical case files was done in thirty cases of glioblastoma (World Health Organization Grade IV). These cases were analyzed for certain defined clinical and histopathological parameters. IHC staining for IDH1-R132H and ATRX was done. IHC scores for p53, EGFR, VEGF, MDM2, and Ki67 were included from the previously published dataset. IHC labeling of all these markers was analyzed, and their interrelationship was studied and correlated with the survival pattern. Results: Cases were categorized as glioblastoma, IDH-wild type; glioblastoma, IDH-mutant; and glioblastoma, not otherwise specified (NOS). A total of 17 cases were categorized as glioblastoma, IDH-wild type and 10 cases were categorized as glioblastoma, IDH-mutant. Three cases in younger adults were categorized as glioblastoma, NOS. In glioblastoma, IDH-wild type, p53 expression was found in 7 cases, increased Ki67 expression was present in 12 cases, VEGF expression was found in 16 cases, MDM2 was expressed in 14 cases, while EGFR expression was present in 10 cases. In glioblastoma, IDH-mutant, p53 expression was found in 5 cases, increased Ki67 expression was present in 4 cases, VEGF expression was found in 9 cases, MDM2 was expressed in 5 cases, while EGFR expression was present in 3 cases. The mean overall survival in glioblastoma, IDH-wild type was 3.1 months and, in glioblastoma, IDH-mutant, the mean overall survival was 6.4 months. Conclusion: Survival pattern of glioblastoma, IDH-mutant, was better than glioblastoma, IDH-wild type.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed458    
    Printed43    
    Emailed0    
    PDF Downloaded56    
    Comments [Add]    

Recommend this journal